ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?

• click to rate

  Posted by Two Blokes Thu at 7:45 PM - Filed in Stock - 2 views
  
  ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025.